ArticleInfection and drug resistance2026
Proteomic Analysis of Cerebrospinal Fluid: Toward the Identification of Biomarkers for Early Central Nervous System Infection.
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Early diagnosis of central nervous system (CNS) infections remains challenging. The aim of this study was to explore and identify potential biomarkers of CNS infection by comparing cerebrospinal fluid (CSF) proteomic characteristics in patients with tuberculous meningitis (TBM), purulent meningitis (PM), and viral meningitis (VM), as well as in patients without CNS infections. Methods: We conducted the first systematic 4D-DIA comparative proteomic analysis of CSF across TBM (N=6), PM (N=6), VM (N=12), and controls (N=12) using pooled samples. Differential proteins were identified, subjected to GO and KEGG enrichment analyses, and used to construct protein-protein interaction networks for hub protein identification. Results: Proteomic analysis revealed significant differences in CSF protein expression profiles among three types of meningitis. In TBM patients, 53 specific proteins were identified, primarily involved in the complement and coagulation cascade as well as the COVID-19-related immune pathway. PPI network analysis highlighted FGA, FGB, C4BPA, and ADAMTS13 as hub proteins exhibiting notably significant expression levels in TBM patients. In PM patients, 9 proteins were identified, predominantly linked to phagosomes and B-cell receptor signaling, with COLEC11 and ESM1 showing significantly higher expression. In VM patients, 29 proteins were identified, mainly associated with complement and coagulation pathways, featuring higher levels of TMED7, MMP17, and CD81. Conclusion: This study delineated the CSF protein profiles in patients with TBM, PM, VM, and non-CNS infections. We identified several potential biomarkers, including FGA, FGB, C4BPA, ADAMTS13, COLEC11, ESM1, TMED7, MMP17, and CD81. Additionally, we proposed hypothetical molecular mechanisms that may offer valuable diagnostic and therapeutic insights for CNS infections. Nonetheless, given that this is a preliminary exploratory study, further validation through multicenter, large-sample cohort studies and functional experiments is necessary to substantiate the clinical relevance and utility of these biomarkers prior to any potential application in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.